Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
4.960
+0.220 (4.64%)
At close: Aug 22, 2025, 4:00 PM
4.910
-0.050 (-1.01%)
After-hours: Aug 22, 2025, 6:31 PM EDT
Precision BioSciences Employees
Precision BioSciences had 108 employees as of December 31, 2024. The number of employees decreased by 1 or -0.92% compared to the previous year.
Employees
108
Change (1Y)
-1
Growth (1Y)
-0.92%
Revenue / Employee
$11,676
Profits / Employee
-$724,583
Market Cap
58.46M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108 | -1 | -0.92% |
| Dec 31, 2023 | 109 | -89 | -44.95% |
| Dec 31, 2022 | 198 | 0 | - |
| Dec 31, 2021 | 198 | -33 | -14.29% |
| Dec 31, 2020 | 231 | 32 | 16.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DTIL News
- 16 days ago - Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 17 days ago - Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Business Wire
- 19 days ago - Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 - Business Wire
- 4 weeks ago - Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
- 5 weeks ago - Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire
- 2 months ago - Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire
- 3 months ago - Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business Wire